BOSTON--(BUSINESS WIRE)--Significantly more patients treated with Pfizer’s Lyrica reduced their pain by 50 percent or more compared with placebo, according to study results presented today at the American Academy of Neurology annual meeting. Clinically, this outcome would equate to a patient with severe pain reporting a reduction to mild to moderate pain.
